Skip to main content

CONTRIBUCION DE ESPECIES LIPIDICAS BIOACTIVAS (ESFINGOSINA-1-FOSFATO) ASOCIADAS A HDL SOBRE LA DISFUNCION MIOCARDICA EN PACIENTES CON DIABETES MELLITUS TIPO 2 Y EFECTO DEL CONTROL GLICEMICO.

PI17/00232

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre HOSPITAL DE LA SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Epicardial Adipose Tissue with Novel Inflammation and Heart Failure Biomarkers in Type 2 Diabetes Patients, Effect of Metabolic Control

  • Gil, Pedro|||0000-0003-3707-7450
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Background : Type 2 diabetes (T2D patients) have a 74% increased risk of heart failure (HF), but traditional HF biomarkers lack sensitivity in early disease detection. Increased epicardial adipose tissue volume (EATv) is associated with cardiovascular risk in T2D, and novel biomarkers such as growth differentiation factor 15 (GDF15), Galectin-3, and soluble suppression of tumorigenicity 2 (sST2) are inflammation biomarkers linked to HF. Methods : We investigated associations between EATv, inflammation biomarkers, and the effect of metabolic control in 14 healthy controls (HCs) and 36 newly diagnosed T2D patients both before (poor glycemic control, PGC) and after 12 months of glycemic optimization (good glycemic control, GGC). EATv indexed to body surface area (iEATv) was quantified by multidetector computed tomography, and biomarker levels were measured by immunoassays. Results : PGC patients had higher iEATv (59.53 ± 21.67 vs. 36.84 ± 16.57 cm 3 /m 2, p = 0.0017) and elevated GDF15, Galectin-3, and sST2 levels (all p < 0.05) than HC subjects. The glycemic optimization reduced iEATv (p = 0.0232) and sST2 (p = 0.048), while GDF15 and Galectin-3 remained unchanged. Multivariable analysis confirmed independent associations between iEATv, GDF15 (β = 0.27, p = 0.027) and sST2 (β = 0.29, p = 0.02). Conclusions : These results support the link between systemic inflammation, EAT expansion, and cardiac dysfunction, and they point to the role of epicardial fat in early HF risk of T2D patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low-Density Lipoprotein Subfraction Phenotype Is Associated with Epicardial Adipose Tissue Volume in Type 2 Diabetes

  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Gil, Pedro|||0000-0003-3707-7450
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Background : Increased epicardial adipose tissue (EAT) volume is a common feature in type 2 diabetes (T2DM) which is directly associated with heart failure and advanced atherosclerosis. We aimed to evaluate lipoprotein-related biomarkers of EAT volume in T2DM patients before and after glycemic control. Methods : This study included 36 T2DM patients before and after optimization of glycemic control and on 14 healthy controls (HCs). EAT volume was measured using computed tomography imaging indexed to the body surface area (iEAT). Biochemical and lipid profiles were determined using commercial methods. Lipoproteins were isolated by ultracentrifugation, and variables of lipoprotein function were assessed. Multivariable regression analysis was used to find variables independently associated with iEAT. Results : iEAT was higher in T2DM than in controls and decreased with glycemic optimization. HDLs from T2DM had less apoA-I and cholesterol and more apoC-III and triglycerides. LDLs from T2DM had more triglycerides and apoB and smaller sizes than those from HCs. Significant correlations were found between iEAT and age, BMI, HbA1c, GGT, VLDLc, triglycerides, LDL size, apoA-I in HDL, and apoC-III in HDL. In the multivariable regression analysis, age, LDL size, and GGT associations remained statistically significant, and predicted 50% of the variability in EAT volume. ROC analysis using these variables showed an AUC of 0.835. Conclusions : Qualitative characteristics of lipoproteins were altered in T2DM. Multivariable analysis showed that LDL size and GGT plasma levels were independently associated with iEAT volume, suggesting that these variables might be useful biomarkers for stratifying T2DM patients with increased EAT volume.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human ApoA-I overexpression enhances macrophage-specific reverse cholesterol transport but fails to prevent inherited diabesity in mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farré, Núria|||0000-0003-3110-6572
  • Santos, David|||0000-0003-1157-4969
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Metso, Jari
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Errico, Teresa Laura
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Human apolipoprotein A-I (hApoA-I) overexpression improves high-density lipoprotein (HDL) function and the metabolic complications of obesity. We used a mouse model of diabesity, the db/db mouse, to examine the effects of hApoA-I on the two main functional properties of HDL, i.e., macrophage-specific reverse cholesterol transport (m-RCT) in vivo and the antioxidant potential, as well as the phenotypic features of obesity. HApoA-I transgenic (hA-I) mice were bred with nonobese control (db/+) mice to generate hApoA-I-overexpressing db/+ offspring, which were subsequently bred to obtain hA-I-db/db mice. Overexpression of hApoA-I significantly increased weight gain and the incidence of fatty liver in db/db mice. Weight gain was mainly explained by the increased caloric intake of hA-I-db/db mice (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide Prevents Apolipoprotein B-Containing Lipoprotein Oxidation, Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Letelier, Nicole
  • Farré, Núria|||0000-0003-3110-6572
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Nieto-Nicolau, Núria|||0000-0002-3527-0110
  • Rodríguez-Millán, Elisabeth
  • Santos, David|||0000-0003-1157-4969
  • Pallarès, Victor|||0000-0002-9851-0345
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Vázquez del Olmo, Tania
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Casaroli-Marano, Ricardo Pedro|||0000-0003-1812-9323
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
The potential of nicotinamide (NAM) to prevent atherosclerosis has not yet been examined. This study investigated the effect of NAM supplementation on the development of atherosclerosis in a mouse model of the disease. The development of aortic atherosclerosis was significantly reduced (NAM low dose: 45%; NAM high dose: 55%) in NAM-treated, apolipoprotein (Apo)E-deficient mice challenged with a Western diet for 4 weeks. NAM administration significantly increased (1.8-fold) the plasma concentration of proatherogenic ApoB-containing lipoproteins in NAM high-dose (HD)-treated mice compared with untreated mice. However, isolated ApoB-containing lipoproteins from NAM HD mice were less prone to oxidation than those of untreated mice. This result was consistent with the decreased (1.5-fold) concentration of oxidized low-density lipoproteins in this group. Immunohistochemical staining of aortas from NAM-treated mice showed significantly increased levels of IL-10 (NAM low-dose (LD): 1.3-fold; NAM HD: 1.2-fold), concomitant with a significant decrease in the relative expression of TNFα (NAM LD: -44%; NAM HD: -57%). An improved anti-inflammatory pattern was reproduced in macrophages cultured in the presence of NAM. Thus, dietary NAM supplementation in ApoE-deficient mice prevented the development of atherosclerosis and improved protection against ApoB-containing lipoprotein oxidation and aortic inflammation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Pérez, Antonio|||0000-0001-5528-1143
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Santos, David|||0000-0003-1157-4969
  • Farré, Núria|||0000-0003-3110-6572
  • Ruiz-Nogales, Sheila
  • Leánez, Sergi
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Zapico Muñiz, Edgar|||0000-0002-8921-1167
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pol, Olga|||0000-0002-4621-8457
The antinociceptive effects of the carbon monoxide-releasing molecule tricarbonyldichlororuthenium (II) dimer (CORM-2) during chronic pain are well documented, but most of its possible side-effects remain poorly understood. In this work, we examine the impact of CORM-2 treatment on the lipoprotein profile and two main atheroprotective functions attributed to high-density lipoprotein (HDL) in a mouse model of type 1 diabetes while analyzing the effect of this drug on diabetic neuropathy. Streptozotocin (Stz)-induced diabetic mice treated with CORM-2 (Stz-CORM-2) or vehicle (Stz-vehicle) were used to evaluate the effect of this drug on the modulation of painful diabetic neuropathy using nociceptive behavioral tests. Plasma and tissue samples were used for chemical and functional analyses, as appropriate. Two main antiatherogenic properties of HDL, i.e., the ability of HDL to protect low-density lipoprotein (LDL) from oxidation and to promote reverse cholesterol transport from macrophages to the liver and feces in vivo (m-RCT), were also assessed. Stz-induced diabetic mice displayed hyperglycemia, dyslipidemia and pain hypersensitivity. The administration of 10 mg/kg CORM-2 during five consecutive days inhibited allodynia and hyperalgesia and significantly ameliorated spinal cord markers (Cybb and Bdkrb1 expression) of neuropathic pain in Stz mice, but it did not reduce the combined dyslipidemia shown in Stz-treated mice. Its administration to Stz-treated mice led to a significant increase in the plasma levels of cholesterol (∼ 1.4-fold vs. Ctrl, ∼ 1.3- fold vs. Stz-vehicle; p < 0.05) and was attributed to significant elevations in both non-HDL (∼ 1.8-fold vs. Ctrl; ∼ 1.6-fold vs. Stz-vehicle; p < 0.05) and HDL cholesterol (∼ 1.3-fold vs. Ctrl, ∼ 1.2-fold vs. Stz-vehicle; p < 0.05). The increased HDL in plasma was not accompanied by a commensurate elevation in m-RCT in Stz-CORM-2 compared to Stz-vehicle mice; instead, it was worsened as revealed by decreased [ 3 H]-tracer trafficking into the feces in vivo. Furthermore, the HDL-mediated protection against LDL oxidation ex vivo shown by the HDL isolated from Stz-CORM-2 mice did not differ from that obtained in Stz-vehicle mice. In conclusion, the antinociceptive effects produced by a high dose of CORM-2 were accompanied by antioxidative effects but were without favorable effects on the dyslipidemia manifested in diabetic mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Canyelles, Marina|||0000-0002-0278-5337
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control

  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Hernández García, Marta|||0000-0003-1237-298X
  • Ortega, Emilio|||0000-0002-2217-8905
  • Amigó, Núria|||0000-0002-0116-9145
  • Real, J.
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Miñambres, Inka|||0000-0002-0899-3938
  • López, C.
  • Lecube, Albert|||0000-0001-9684-0183
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mauricio, Didac|||0000-0002-2868-0250
Aims: The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined. Methods: We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7.0%). Results: Advanced lipoprotein analysis revealed a significant reduction from baseline in serum concentrations of triglycerides (TG), cholesterol (C), and apolipoprotein (Apo)B-containing lipoproteins of treated subjects (VLDL-TG: -21%, IDL-TG: -30%, LDL-TG: -34%, LDL-TG: -36%, P < 0.05; VLDL-C: -23%, IDL-C: -44%, LDL-C: -16%; p < 0.05). Decreased VLDL and LDL lipids were mainly attributed to concomitant reductions in the concentration of medium-sized VLDL (-36%) and medium-sized LDL (-31%) and, to a lesser extent, to large-sized LDL (-14%). Notably, proatherogenic IDL characteristics and related surrogates of atherogenicity were resolved upon achievement of optimal glycemic status. Moreover, the concentration of HDL-TG was also reduced (-18%) at follow-up. Conclusions: Our data showed that the achievement of optimal glycemic control after T1D onset corrected hidden derangements in ApoB-containing lipoproteins (particularly IDL) and HDL-TG that are related to higher cardiovascular risk in poorly controlled T1D.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases

  • Rotllan, Noemi|||0000-0002-0587-8045
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Canyelles, Marina|||0000-0002-0278-5337
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Benitez, Sonia|||0000-0003-3565-0743
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic stress directly impact the cardiovascular system. Over the last few years, the contributions of altered nicotinamide adenine dinucleotide (NAD+) metabolism to aging and other pathological conditions closely related to cardiovascular diseases have been intensively investigated. NAD+ bioavailability decreases with age and cardiometabolic conditions in several mammalian tissues. Compelling data suggest that declining tissue NAD+ is commonly related to mitochondrial dysfunction and might be considered as a therapeutic target. Thus, NAD+ replenishment by either genetic or natural dietary NAD+-increasing strategies has been recently demonstrated to be effective for improving the pathophysiology of cardiac and vascular health in different experimental models, as well as human health, to a lesser extent. Here, we review and discuss recent experimental evidence illustrating that increasing NAD+ bioavailability, particularly by the use of natural NAD+ precursors, may offer hope for new therapeutic strategies to prevent and treat cardiovascular diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy

  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Correig Fraga, Eudald|||0000-0001-8556-0469
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Amigó, Núria|||0000-0002-0116-9145
  • Hernández García, Marta|||0000-0003-1237-298X
  • Traveset, Alicia|||0000-0003-2703-326X
  • Carbonell Puig, Marc
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
This study aimed to assess whether the advanced characteristics of serum lipoprotein subclasses could better predict the risk of developing diabetic retinopathy (DR) and its severity compared to other established risk factors in subjects with type 1 (T1D) and type 2 (T2D) diabetes. This observational, cross-sectional substudy analyzed DR-related data from 309 T1D and 264 T2D subjects. The advanced lipoprotein and glycoprotein profile was determined by nuclear magnetic resonance (NMR) spectroscopy (Liposcale test). NMR analysis of lipoproteins revealed that T1D subjects with DR showed standard non-HDL particles, despite higher IDL lipid concentrations. Notably, IDL lipids were elevated in T1D subjects with worsened DR. VLDL and LDL were smaller, whereas HDL triglycerides were increased in DR compared with non-DR. On the other hand, the T2D subjects with DR showed altered characteristics in the LDL fraction, mainly revealed by a significant decrease in smaller LDL and a reduction in LDL-C. Moreover, the glycoprotein profile did not reveal significant changes among DR groups, regardless of the type of diabetes. However, lipoprotein characteristics and glycoproteins unveiled by NMR analysis did not improve the predictive value of conventional lipids or other traditional, well-established biomarkers of DR in our cohorts.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nicotinamide protects against diet-induced body weight gain, increases energy expenditure, and induces white adipose tissue beiging

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Rodríguez-Millán, Elisabeth
  • Sebastián, David|||0000-0002-7260-3869
  • Blanco-Soto, Rosi
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Mato, Eugènia|||0000-0001-8121-9335
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Roglans, Núria
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Villena, Josep A.|||0000-0002-2200-2985
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Scope: Interventions that boost NAD+ availability are of potential therapeutic interest for obesity treatment. The potential of nicotinamide (NAM), the amide form of vitamin B3 and a physiological precursor of nicotinamide adenine dinucleotide (NAD)+, in preventing weight gain has not previously been studied in vivo. Other NAD+ precursors have been shown to decrease weight gain; however, their impact on adipose tissue is not addressed. Methods and results: Two doses of NAM (high dose: 1% and low dose: 0.25%) are given by drinking water to C57BL/6J male mice, starting at the same time as the high-fat diet feeding. NAM supplementation protects against diet-induced obesity by augmenting global body energy expenditure in C57BL/6J male mice. The manipulation markedly alters adipose morphology and metabolism, particularly in inguinal (i) white adipose tissue (iWAT). An increased number of brown and beige adipocyte clusters, protein abundance of uncoupling protein 1 (UCP1), mitochondrial activity, adipose NAD+, and phosphorylated AMP-activated protein kinase (P-AMPK) levels are observed in the iWAT of treated mice. Notably, a significant improvement in hepatic steatosis, inflammation, and glucose tolerance is also observed in NAM high-dose treated mice. Conclusion: NAM influences whole-body energy expenditure by driving changes in the adipose phenotype. Thus, NAM is an attractive potential treatment for preventing obesity and associated complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Purpose of Review: We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH). Recent Findings: RCT from macrophages (m-RCT), a vascular cell type of major influence on atherosclerosis, is impaired in FH due to defective low-density lipoprotein receptor (LDLR) function via both the HDL- and LDL-mediated pathways. Potential mechanisms include impaired HDL metabolism, which is linked to increased LDL levels, as well as the increased transport of cellular unesterified cholesterol to LDL, which presents a defective catabolism. Summary: RCT dysfunction is consistently associated with mutation-positive FH linked to decreased HDL levels as well as impaired HDL remodeling and LDLR function. It remains to be explored whether these alterations are also present in less well-characterized forms of FH, such as cases with no identified mutations, and whether they are fully corrected by current standard treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus

  • Rodríguez-Calvo, Ricardo|||0000-0001-7513-0983
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julián, María Teresa|||0000-0003-2524-1823
  • Domingo, Mar|||0000-0002-2935-1272
  • Codina, Pau|||0000-0002-2469-5711
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Cediel, Germán|||0000-0001-9667-7507
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rossell, Joana|||0000-0003-1500-6379
  • Masana, Luis|||0000-0002-0789-4954
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9-3440.5) pg/mL vs. 1396.05 (820.3-2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6-79.8) ng/mL vs. 34.1 (24.09-55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09-1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12-4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09-1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21-7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11-3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport

  • Hueso, Miguel|||0000-0002-1824-9141
  • Griñán, Raquel|||0000-0002-9457-3365
  • Mallen, Adrián
  • Navarro, Estanislao
  • Purqueras, Elvira
  • Gomà-Gállego, Montserrat
  • Sbraga, Fabrizio
  • Blasco-Lucas, Arnau|||0000-0002-2796-7428
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Santos, David|||0000-0003-1157-4969
  • Canyelles, Marina|||0000-0002-0278-5337
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
Objective: To determine whether miR-125b regulates cholesterol efflux in vivo and in vitro through the regulation of scavenger receptor type B1 (SR-B1). Approach and results: We demonstrated that miR-125b is up-regulated in the human aortas of patients with CAD and is located in macrophages and vascular smooth muscle cells (VSMCs). We identified SCARB1 as a direct target of miR-125b by repressing the activity of the SCARB1 3'-untranslated region reporter construct. Moreover, the overexpression of miR-125b in both human and mouse macrophages as well as VSMCs was found to downregulated the expression of the SCARB1 and the SR-B1 protein levels, thereby impairing α-HDL-mediated macrophage cholesterol efflux in vitro. The in vivo reverse cholesterol transport (RCT) rate from non-cholesterol-loaded macrophages transfected with miR-125b to feces was also found to be decreased when compared with that of control mimic-transfected macrophages. Conclusions: Together, these results provide evidence that miR-125b downregulates SCARB1 and SR-B1 in both human and mouse macrophages as well as VSMCs, thereby impairing macrophage cholesterol efflux in vitro and the whole macrophage-specific RCT pathway in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus

  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Julián, María Teresa|||0000-0003-2524-1823
  • Amigó, Núria|||0000-0002-0116-9145
  • Andersen, Henrik U.
  • Ahluwalia, Tarunveer Singh|||0000-0002-7464-3354
  • Rossing, Peter|||0000-0002-1531-4294
  • Mauricio, Didac|||0000-0002-2868-0250
  • Jensen, Magnus T.
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e'≥12 or E/e' 8-12 + volume of the left atrium.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro|||0000-0003-3707-7450
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garcia-Moll, Xavier|||0000-0001-7837-8378
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez, Antonio|||0000-0001-5528-1143
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c.